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Solvent electrospinning
Solvent electrospinning transforms a crystalline
drug into an amorphous one, increasing its
solubility. Moreover, the technique is fast and
cheap.
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Thermal analysis
Our analysis shows that our drugs are
completely monophasic and amorphous
(through mDSC) with a glass transition
temperature above room temperature.
This confirms their homogeneity and
time stability.
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Combining the considerable increase in drug release with a homogeneous and time stable material, the
high potential of solvent electrospinning poorly water-soluble drugs with a polymeric matrix is proven!
Over 2/3rd of all newly developed drugs are rendered useless
because they don’t dissolve in our stomach! Their high
crystallinity prevents any active ingredients from entering our
system.
As other techniques prove to be insufficient, we develop a
new oral formulation based on solvent electrospinning to
give these drugs their full healing potential.
Dissolution testing
A significantly increased solubility of the drug in
aqueous environment is shown.
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